Daniel E. Morse
Corporate Officer/Principal at University of California, Santa Barbara
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jack Krouskup | M | 74 |
University of California, Santa Barbara
| 12 years |
| Yulun Wang | M | - |
University of California, Santa Barbara
| 4 years |
| Robert Wilkinson | M | - |
University of California, Santa Barbara
| - |
| James G. P. Dehlsen | M | - |
University of California, Santa Barbara
| - |
| Klaus Schauser | M | 61 |
University of California, Santa Barbara
| - |
| Bradley E. Paden | M | - |
University of California, Santa Barbara
| - |
| Claude Weisbuch | M | - |
University of California, Santa Barbara
| - |
| Richard Wolski | M | - |
University of California, Santa Barbara
| - |
| James Speck | M | - |
University of California, Santa Barbara
| - |
| Steven DenBaars | M | 62 |
University of California, Santa Barbara
| 33 years |
| Samir Mitragotri | M | - |
University of California, Santa Barbara
| - |
| Umesh K. Mishra | M | 66 |
University of California, Santa Barbara
| 34 years |
| Hyongsok Soh | M | - |
University of California, Santa Barbara
| - |
| Jenny McCahill | M | - |
University of California, Santa Barbara
| - |
| Alan W. Hoffman | M | - |
University of California, Santa Barbara
| 30 years |
| Christopher Kruegel | M | - |
University of California, Santa Barbara
| - |
| Glenn Fredrickson | M | 65 |
University of California, Santa Barbara
| 34 years |
| Huican Zhu | M | - |
University of California, Santa Barbara
| 6 years |
| Jonathan Klamkin | M | 44 |
University of California, Santa Barbara
| 9 years |
| Roman Baratiak | M | - |
University of California, Santa Barbara
| - |
| Patrick S. Daugherty | M | - |
University of California, Santa Barbara
| - |
| Subhash Suri | M | - |
University of California, Santa Barbara
| - |
| John R. Mackall | M | 74 |
University of California, Santa Barbara
| - |
| John Marren | M | 61 |
University of California, Santa Barbara
| - |
| Daryl Stemm | M | 64 |
University of California, Santa Barbara
| - |
| Henry T. Yang | M | 82 |
University of California, Santa Barbara
| - |
| David J. Adornetto | M | - |
University of California, Santa Barbara
| - |
| Martin Moskovits | M | 81 |
University of California, Santa Barbara
| - |
| Nadir Dagli | M | - |
University of California, Santa Barbara
| 37 years |
| Frederick Gluck | M | 88 |
University of California, Santa Barbara
| - |
| W. Roger Haughton | M | 76 |
University of California, Santa Barbara
| - |
| Daniel Burnham | M | 77 |
University of California, Santa Barbara
| - |
| John Dorman | M | 73 |
University of California, Santa Barbara
| - |
| Howard Wenger | M | 64 |
University of California, Santa Barbara
| - |
| Daniel Vapnek | M | 85 |
University of California, Santa Barbara
| - |
| John E. Bowers | M | - |
University of California, Santa Barbara
| - |
| Alan Heeger | M | - |
University of California, Santa Barbara
| 42 years |
| William A. Dinsmore | M | - |
University of California, Santa Barbara
| - |
| Robert F. Preston | M | 66 |
University of California, Santa Barbara
| - |
| Hua Lee | M | 72 |
University of California, Santa Barbara
| 34 years |
| Matthew V. Tirrell | M | - |
University of California, Santa Barbara
| - |
| Stephen E. Cooper | M | 78 |
University of California, Santa Barbara
| - |
| Robert C. Lowes | M | - |
University of California, Santa Barbara
| - |
| Jack Wolever | M | - |
University of California, Santa Barbara
| - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Darrell H. Brookstein | M | 72 |
Stellar Biotechnologies, Inc. /Old/
CAG Capital, Inc.
 CAG Capital, Inc. Financial ConglomeratesFinance CAG Capital Inc. is a capital pool company. The company's principal business is to identify and evaluate businesses and assets and, once identified and evaluated, to negotiate an acquisition subject to receipt of the approval of the TSX venture exchange. The company has not conducted commercial operations other than to enter into discussions for the purpose of identifying potential acquisitions or interest.
Stellar Biotechnologies, Inc.
 Stellar Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology Stellar Biotechnologies, Inc. engages in the research, development, manufacture, and commercialization of Keyhole Limpet Hemocyanin (KLH), an immune-stimulating protein utilized as a carrier molecule in therapeutic vaccines and for assessing immune system function. Its product portfolio includes Stellar KLH Products, Stellar KLH Protein, and Stellar KLH ELISA Kits. The Company was founded in 1999 and is headquartered in Port Hueneme, CA. | 5 years |
| Frank Oakes | M | 73 |
Stellar Biotechnologies, Inc. /Old/
CAG Capital, Inc.
CAG Capital, Inc. Financial ConglomeratesFinance CAG Capital Inc. is a capital pool company. The company's principal business is to identify and evaluate businesses and assets and, once identified and evaluated, to negotiate an acquisition subject to receipt of the approval of the TSX venture exchange. The company has not conducted commercial operations other than to enter into discussions for the purpose of identifying potential acquisitions or interest.
Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology Stellar Biotechnologies, Inc. engages in the research, development, manufacture, and commercialization of Keyhole Limpet Hemocyanin (KLH), an immune-stimulating protein utilized as a carrier molecule in therapeutic vaccines and for assessing immune system function. Its product portfolio includes Stellar KLH Products, Stellar KLH Protein, and Stellar KLH ELISA Kits. The Company was founded in 1999 and is headquartered in Port Hueneme, CA. | 9 years |
| Gregory T. Baxter | M | 64 |
Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology Stellar Biotechnologies, Inc. engages in the research, development, manufacture, and commercialization of Keyhole Limpet Hemocyanin (KLH), an immune-stimulating protein utilized as a carrier molecule in therapeutic vaccines and for assessing immune system function. Its product portfolio includes Stellar KLH Products, Stellar KLH Protein, and Stellar KLH ELISA Kits. The Company was founded in 1999 and is headquartered in Port Hueneme, CA. | 7 years |
| Catherine Brisson | M | 50 |
Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology Stellar Biotechnologies, Inc. engages in the research, development, manufacture, and commercialization of Keyhole Limpet Hemocyanin (KLH), an immune-stimulating protein utilized as a carrier molecule in therapeutic vaccines and for assessing immune system function. Its product portfolio includes Stellar KLH Products, Stellar KLH Protein, and Stellar KLH ELISA Kits. The Company was founded in 1999 and is headquartered in Port Hueneme, CA. | 6 years |
| Peter Mikel Jankovskis | M | - |
University of California, Santa Barbara
| 12 years |
| Jonathan Siegel | M | - |
University of California, Santa Barbara
| 14 years |
| Kathi Niffenegger | F | 67 |
Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology Stellar Biotechnologies, Inc. engages in the research, development, manufacture, and commercialization of Keyhole Limpet Hemocyanin (KLH), an immune-stimulating protein utilized as a carrier molecule in therapeutic vaccines and for assessing immune system function. Its product portfolio includes Stellar KLH Products, Stellar KLH Protein, and Stellar KLH ELISA Kits. The Company was founded in 1999 and is headquartered in Port Hueneme, CA. | - |
| Gustavo Alonso | M | 59 |
University of California, Santa Barbara
| 3 years |
| José Herrero Sáenz de Cabezón | M | 69 |
University of California, Santa Barbara
| 6 years |
| David C. Spaulding | M | - |
University of California, Santa Barbara
| 10 years |
| Robert Kelly Moore | M | - |
University of California, Santa Barbara
| 9 years |
| David L. Hill | M | 73 |
Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology Stellar Biotechnologies, Inc. engages in the research, development, manufacture, and commercialization of Keyhole Limpet Hemocyanin (KLH), an immune-stimulating protein utilized as a carrier molecule in therapeutic vaccines and for assessing immune system function. Its product portfolio includes Stellar KLH Products, Stellar KLH Protein, and Stellar KLH ELISA Kits. The Company was founded in 1999 and is headquartered in Port Hueneme, CA. | - |
| Ashley Newsom Giesler | F | - |
University of California, Santa Barbara
| - |
| W. Catalano | M | 59 |
CAG Capital, Inc.
CAG Capital, Inc. Financial ConglomeratesFinance CAG Capital Inc. is a capital pool company. The company's principal business is to identify and evaluate businesses and assets and, once identified and evaluated, to negotiate an acquisition subject to receipt of the approval of the TSX venture exchange. The company has not conducted commercial operations other than to enter into discussions for the purpose of identifying potential acquisitions or interest.
Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology Stellar Biotechnologies, Inc. engages in the research, development, manufacture, and commercialization of Keyhole Limpet Hemocyanin (KLH), an immune-stimulating protein utilized as a carrier molecule in therapeutic vaccines and for assessing immune system function. Its product portfolio includes Stellar KLH Products, Stellar KLH Protein, and Stellar KLH ELISA Kits. The Company was founded in 1999 and is headquartered in Port Hueneme, CA. | 3 years |
| Alexander W. Fang | M | - |
University of California, Santa Barbara
| 4 years |
| Mayank D. Sampat | M | 68 |
Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology Stellar Biotechnologies, Inc. engages in the research, development, manufacture, and commercialization of Keyhole Limpet Hemocyanin (KLH), an immune-stimulating protein utilized as a carrier molecule in therapeutic vaccines and for assessing immune system function. Its product portfolio includes Stellar KLH Products, Stellar KLH Protein, and Stellar KLH ELISA Kits. The Company was founded in 1999 and is headquartered in Port Hueneme, CA. | - |
| Amandeep S. Anand | M | - |
University of California, Santa Barbara
| 6 years |
| Raffaello Colasante | M | - |
University of California, Santa Barbara
| 5 years |
| Charles Olson | M | 66 |
Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology Stellar Biotechnologies, Inc. engages in the research, development, manufacture, and commercialization of Keyhole Limpet Hemocyanin (KLH), an immune-stimulating protein utilized as a carrier molecule in therapeutic vaccines and for assessing immune system function. Its product portfolio includes Stellar KLH Products, Stellar KLH Protein, and Stellar KLH ELISA Kits. The Company was founded in 1999 and is headquartered in Port Hueneme, CA. | - |
| Deborah F. Aghib | M | 65 |
Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology Stellar Biotechnologies, Inc. engages in the research, development, manufacture, and commercialization of Keyhole Limpet Hemocyanin (KLH), an immune-stimulating protein utilized as a carrier molecule in therapeutic vaccines and for assessing immune system function. Its product portfolio includes Stellar KLH Products, Stellar KLH Protein, and Stellar KLH ELISA Kits. The Company was founded in 1999 and is headquartered in Port Hueneme, CA. | - |
| Hui Li | M | 57 |
University of California, Santa Barbara
| 3 years |
| Namvar Kiaie | M | - |
University of California, Santa Barbara
| 5 years |
| Wei-Ying Ma | M | 55 |
University of California, Santa Barbara
| 4 years |
| Herbert S. Chow | M | 69 |
Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology Stellar Biotechnologies, Inc. engages in the research, development, manufacture, and commercialization of Keyhole Limpet Hemocyanin (KLH), an immune-stimulating protein utilized as a carrier molecule in therapeutic vaccines and for assessing immune system function. Its product portfolio includes Stellar KLH Products, Stellar KLH Protein, and Stellar KLH ELISA Kits. The Company was founded in 1999 and is headquartered in Port Hueneme, CA. | 4 years |
| Harvey S. Wright | M | 88 |
Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology Stellar Biotechnologies, Inc. engages in the research, development, manufacture, and commercialization of Keyhole Limpet Hemocyanin (KLH), an immune-stimulating protein utilized as a carrier molecule in therapeutic vaccines and for assessing immune system function. Its product portfolio includes Stellar KLH Products, Stellar KLH Protein, and Stellar KLH ELISA Kits. The Company was founded in 1999 and is headquartered in Port Hueneme, CA. | - |
| Bhaskar Ramamurthi | M | 65 |
University of California, Santa Barbara
| 4 years |
| Paul Chun | M | 43 |
Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology Stellar Biotechnologies, Inc. engages in the research, development, manufacture, and commercialization of Keyhole Limpet Hemocyanin (KLH), an immune-stimulating protein utilized as a carrier molecule in therapeutic vaccines and for assessing immune system function. Its product portfolio includes Stellar KLH Products, Stellar KLH Protein, and Stellar KLH ELISA Kits. The Company was founded in 1999 and is headquartered in Port Hueneme, CA. | - |
| Trung Tri Doan | M | 65 |
University of California, Santa Barbara
| 6 years |
| Jeffrey Shealy | M | 55 |
University of California, Santa Barbara
| 4 years |
| Martin Woodward | M | 56 |
CAG Capital, Inc.
CAG Capital, Inc. Financial ConglomeratesFinance CAG Capital Inc. is a capital pool company. The company's principal business is to identify and evaluate businesses and assets and, once identified and evaluated, to negotiate an acquisition subject to receipt of the approval of the TSX venture exchange. The company has not conducted commercial operations other than to enter into discussions for the purpose of identifying potential acquisitions or interest.
Stellar Biotechnologies, Inc. /Old/
| 3 years |
| Hash Pakbaz | M | - |
University of California, Santa Barbara
| 10 years |
| Michael K. Flatten | M | - |
University of California, Santa Barbara
| 6 years |
| Mark McCamish | M | 72 |
University of California, Santa Barbara
| 5 years |
| Kerry Beamish | M | - |
Stellar Biotechnologies, Inc. /Old/
Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology Stellar Biotechnologies, Inc. engages in the research, development, manufacture, and commercialization of Keyhole Limpet Hemocyanin (KLH), an immune-stimulating protein utilized as a carrier molecule in therapeutic vaccines and for assessing immune system function. Its product portfolio includes Stellar KLH Products, Stellar KLH Protein, and Stellar KLH ELISA Kits. The Company was founded in 1999 and is headquartered in Port Hueneme, CA. | - |
| Gary Koppenjan | M | - |
Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology Stellar Biotechnologies, Inc. engages in the research, development, manufacture, and commercialization of Keyhole Limpet Hemocyanin (KLH), an immune-stimulating protein utilized as a carrier molecule in therapeutic vaccines and for assessing immune system function. Its product portfolio includes Stellar KLH Products, Stellar KLH Protein, and Stellar KLH ELISA Kits. The Company was founded in 1999 and is headquartered in Port Hueneme, CA. | 3 years |
| Angela Belcher | M | - |
University of California, Santa Barbara
| 8 years |
| Roger Kjensrud | M | - |
University of California, Santa Barbara
| 3 years |
| Bill Groener | M | - |
University of California, Santa Barbara
| 8 years |
| Duane A. Louderback | M | - |
University of California, Santa Barbara
| 5 years |
| Jack Ucciferri | M | - |
University of California, Santa Barbara
| 6 years |
| Julia Margaret Peter-Kerr | F | - |
University of California, Santa Barbara
| 4 years |
| Brandon D. Heiken | M | - |
University of California, Santa Barbara
| 2 years |
| Gautam Barua | M | 70 |
University of California, Santa Barbara
| 3 years |
| Gideon Samuel Bernstein | M | - |
University of California, Santa Barbara
| 4 years |
| Alex Racioppi | M | - |
University of California, Santa Barbara
| 4 years |
| Jeffrey D Butler | M | - |
University of California, Santa Barbara
| 4 years |
| Christine Marie Kugler | F | - |
University of California, Santa Barbara
| 4 years |
| Shawn Alt | M | - |
University of California, Santa Barbara
| 4 years |
| Jacquelynne Bohlen | F | - |
University of California, Santa Barbara
| 4 years |
| Simon Mosk-Aoyama | M | - |
University of California, Santa Barbara
| 4 years |
| Peter Buckland | M | 54 |
University of California, Santa Barbara
| 4 years |
| Fred Hughes | M | - |
University of California, Santa Barbara
| 4 years |
| David W. M. Harvey | M | - |
University of California, Santa Barbara
| 4 years |
| Adam Krejcik | M | 43 |
University of California, Santa Barbara
| 4 years |
| Gena M. Svedise | F | - |
University of California, Santa Barbara
| 4 years |
| Daniel Ginnetti | M | 55 |
University of California, Santa Barbara
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
| Canada | 4 | 4.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Daniel E. Morse
- Personal Network
